In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients / Malapelle, U.; Rossi, G.; Pisapia, P.; Barberis, M.; Buttitta, F.; Castiglione, F.; Cecere, F. L.; Grimaldi, A. M.; Iaccarino, A.; Marchetti, A.; Massi, D.; Medicina, D.; Mele, F.; Minari, R.; Orlando, E.; Pagni, F.; Palmieri, G.; Righi, L.; Russo, A.; Tommasi, S.; Vermi, W.; Troncone, G.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 156:(2020), p. 103118. [10.1016/j.critrevonc.2020.103118]

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Barberis M.;Palmieri G.
Investigation
;
Russo A.;
2020-01-01

Abstract

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided.
2020
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients / Malapelle, U.; Rossi, G.; Pisapia, P.; Barberis, M.; Buttitta, F.; Castiglione, F.; Cecere, F. L.; Grimaldi, A. M.; Iaccarino, A.; Marchetti, A.; Massi, D.; Medicina, D.; Mele, F.; Minari, R.; Orlando, E.; Pagni, F.; Palmieri, G.; Righi, L.; Russo, A.; Tommasi, S.; Vermi, W.; Troncone, G.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 156:(2020), p. 103118. [10.1016/j.critrevonc.2020.103118]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/246130
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 15
social impact